We invite you to learn more about our history. Phase 2 data for pimavanserin in patients with dementia-related psychosis published in The Lancet Neurology. Acadia announces positive results in Alzheimer's disease psychosis and initiates studies with pimavanserin for major depressive disorder and schizophrenia.
Acadia reports positive Phase 2 data for pimavanserin in patients with Alzheimer's disease psychosis. FDA and is granted Priority Review. Acadia regains full worldwide rights to pimavanserin following the conclusion of its collaboration with Biovail.
Acadia forms collaboration with Biovail to develop and commercialize pimavanserin in North America. Primary Office. What you see here scratches the surface Request a free trial. Want to dig into this profile? Public Fundamental Data provided by Morningstar, Inc. Request a free trial. HQ Location. Total Raised. Post Valuation. Last Financing Details. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address. San Diego, CA.
Excepteur sint occaecat cupidatat. Cambridge, MA. Ut enim ad minim veniam, quis nostr. Paris, France. Add Comparison. Growth Rate 0. Weekly Growth 0. Size Multiple x Median. All rights reserved. Data Disclaimer Help Suggestions. Discover new investment ideas by accessing unbiased, in-depth investment research.
Stephen R. Srdjan R. VP, Gen. Interim CFO, Sr. VP of Bus. Brendan Teehan. James K.
0コメント